Amarin | AMRN - Trade Debtors


Amarin reported $127.31M in Trade Debtors for its fiscal quarter ending in September of 2025.





Trade Debtors Change Date
AbbVie USD 12.77B 132M Sep/2025
Alnylam Pharmaceuticals USD 777.57M 187.2M Dec/2025
Amarin USD 127.31M 8.18M Sep/2025
AstraZeneca USD 19.05B 1.49B Dec/2025
BioCryst Pharmaceuticals USD 79.07M 6.61M Dec/2024
DBV Technologies USD 15.97M 279K Sep/2025
Esperion Therapeutics USD 60.36M 5.75M Jun/2024
GlaxoSmithKline GBP 7.76B 545M Dec/2025
Halozyme Therapeutics USD 441.27M 95.24M Dec/2025
Heron Therapeutics USD 67.04M 6.9M Sep/2024
Ionis Pharmaceuticals USD 66M 41.39M Dec/2025
Nektar Therapeutics USD 0 2.9M Sep/2024
Neurocrine Biosciences USD 686.8M 41.2M Dec/2025
Novartis USD 8.98B 192M Sep/2025